News for Livzon Pharmaceutical Group Inc. (000513.SZ)

Published at

Oct 4, 2022 5:00 AM

by prnewswire.com

mixed

mixed

Immunosuppressants Market Size to Grow by USD 6.69 billion with Expected YOY of 5.3% in 2022 - Technavio

/PRNewswire/ -- The latest market analysis report titled Immunosuppressants Market by Drug Class and Geography - Forecast and Analysis 2022-2026 has been added...

ABBV34.SA ABBV.MX ABBV.BA ABBV 4AB.DE VTRSV VTRS.MX VTRS VIA.DE TFFP PFED.BA PFECL.SN PFE.SN PFE.MX PFE.DE PFE NVSN.MX NVSEF NVSD.BA NVS NOVN.SW N1VS34.SA GSK.L GSK GS7.DE GLAXF ALPMY ALPMF 4503N.MX 1513.HK 0K9E.L 000513.SZ

Read more →
Published at

Sep 4, 2022 9:11 PM

by economictimes.indiatimes.com

mixed

mixed

CanSino's inhaled Covid-19 vax gets emergency use nod in China

The inhaled version of Cansino's adenovirus-vectored Covid-19 vaccine has obtained the green light from the National Medical Products Administration, the company said in a filing on Sunday.

1513.HK 000513.SZ CASBF 688185.SS 6185.HK

Read more →
Published at

Jan 4, 2022 3:30 AM

by prnewswire.com

mixed

mixed

Leuprolide Acetate Market to Record 10.42% Y-O-Y Growth Rate in 2022 |Evolving Opportunities with AbbVie Inc. & Astellas Pharma Inc. | 17000+ Technavio Reports

/PRNewswire/ -- Technavio's latest research report on the Leuprolide Acetate Market offers a comprehensive analysis on new product launches, the latest trends,...

BFEHF BANB.SW ALPMY ALPMF ABBV34.SA ABBV.MX ABBV.BA ABBV 4AB.DE 4503N.MX 1513.HK 0QND.L 000513.SZ SUNPHARMA-BL.NS

Read more →
Published at

Nov 16, 2021 6:04 PM

by financialpost.com

positive

positive

Bright Peak Therapeutics Licenses Rights to Livzon's Anti-PD-1 Antibody LZM009 to Develop Novel PD-1 Targeted Immunocytokines

SAN DIEGO and BASEL, Switzerland, Nov. 16, 2021 (GLOBE NEWSWIRE) — Bright Peak Therapeutics, Inc., a biotechnology company developing next-generation…

1513.HK 000513.SZ

Read more →
Published at

Nov 16, 2021 6:00 PM

by globenewswire.com

negative

negative

Bright Peak Therapeutics lizenziert Rechte an Anti-PD-1-Antikörper LZM009 von Livzon zur Entwicklung neuartiger, auf PD-1 abzielender Immunzytokine

SAN DIEGO und BASEL, Schweiz, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Bright Peak Therapeutics, Inc., ein Biotechnologieunternehmen, das Zytokin-Immuntherapien...

1513.HK 000513.SZ

Read more →
Published at

Sep 10, 2021 7:38 PM

by gurufocus.com

mixed

mixed

Cai Xiang Yang @ Hua Xia Ji Jin Buys Jiangsu Yanghe Brewery JSC, Chongqing Zhifei Biological Products Co, Changchun High and New Technology Industry Group I, Sells Midea Group Co, Aier Eye Hospital Gr

GuruFocus Article or News written by insider and the topic is about:

603833.SS 600079.SS 300015.SZ 1513.HK 000858.SZ 000568.SZ 000513.SZ FYGGY 603369.SS 600867.SS 600660.SS 3606.HK 300601.SZ 300452.SZ 300122.SZ 000333.SZ

Read more →
Published at

Aug 26, 2021 3:45 PM

by marketscreener.com

neutral

neutral

Livzon Pharmaceutical : China Livzon Pharma affiliate's COVID-19 vaccine candidate enters phase III trial

A potential COVID-19 vaccine developed by a biotech firm affiliated with China's Livzon Pharmaceutical Group Inc has entered a late-stage trial, Livzon said late on Thursday. A Phase... | August 26, 2021

1513.HK 000513.SZ

Read more →
Published at

Jul 9, 2021 11:29 AM

by financialpost.com

positive

positive

Livzon's COVID-19 vaccine appears safe, triggers antibodies -study

BEIJING — A potential COVID-19 vaccine developed by a subsidiary of China’s Livzon Pharmaceutical Group Inc appeared safe and able to elicit antibodies in…

1513.HK 000513.SZ

Read more →
Published at

Mar 23, 2021 3:40 PM

by financialpost.com

positive

positive

China approves clinical trials for Livzon Pharma unit's COVID-19 vaccine

BEIJING — China’s medical products regulator has approved clinical trials for a COVID-19 vaccine candidate developed by a subsidiary of Livzon Pharmaceutical…

CASBF 688185.SS 6185.HK 1513.HK 000513.SZ

Read more →
Published at

Jan 7, 2021 2:01 PM

by thestreet.com

neutral

neutral

CARISMA Therapeutics Completes Series B Funding For $47 Million To Advance Development Of Novel CAR-Macrophage Immunotherapies

PHILADELPHIA, Jan. 7, 2021 /PRNewswire/ -- CARISMA Therapeutics Inc., a biopharmaceutical company focused on discovering and developing innovative

LP6.F LP6.BE 1513.HK 000513.SZ

Read more →
Published at

Jan 7, 2021 1:00 AM

by vcaonline.com

neutral

neutral

Venture Capital Access Online

CARISMA Therapeutics Completes Series B Funding for $47 Million to Advance Development of Novel CAR-Macrophage Immunotherapies PHILADELPHIA, January 7, 2021-- C...

LP6.F LP6.BE 1513.HK 000513.SZ

Read more →